Get the Stockscreener App
14.50
0.07%
0.010
After Hours:
14.29
-0.21
-1.45%
Gh Research Plc stock is traded at $14.50, with a volume of 327.28K.
It is up +0.07% in the last 24 hours and up +21.95% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$14.49
Open:
$14.49
24h Volume:
327.28K
Relative Volume:
1.65
Market Cap:
$754.41M
Revenue:
-
Net Income/Loss:
$-41.43M
P/E Ratio:
-18.35
EPS:
-0.79
Net Cash Flow:
$-39.97M
1W Performance:
-17.47%
1M Performance:
+21.95%
6M Performance:
+64.21%
1Y Performance:
+22.78%
1-Day Range:
$14.18
$14.63
1-Week Range:
$13.62
$19.51
52-Week Range:
$6.00
$20.50
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
14.50 | 898.81M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
Should I hold or sell GH Research PLC stock in 2025Get daily updates on promising stocks - jammulinksnews.com
How volatile is GH Research PLC stock compared to the marketExceptional stock performance - jammulinksnews.com
What is the dividend policy of GH Research PLC stockBuild wealth with high-performing stocks - jammulinksnews.com
When is GH Research PLC stock expected to show significant growthRapid wealth multiplication - jammulinksnews.com
How strong is GH Research PLC company’s balance sheetHigh-profit stock alerts - jammulinksnews.com
How does GH Research PLC generate profit in a changing economyMaster stock selection with insider knowledge - jammulinksnews.com
What is GH Research PLC company’s growth strategyDiscover undervalued opportunities early - jammulinksnews.com
How many analysts rate GH Research PLC as a “Buy”Free Predictions - jammulinksnews.com
What analysts say about GH Research PLC stockUnprecedented profits - PrintWeekIndia
What drives GH Research PLC stock priceConsistent wealth multiplication - PrintWeekIndia
GH Research PLC Stock Analysis and ForecastPowerful growth strategies - PrintWeekIndia
JMP reiterates Market Outperform rating on GH Research stock at $39 target By Investing.com - Investing.com South Africa
JMP reiterates Market Outperform rating on GH Research stock at $39 target - Investing.com
GH Research's GH001: A Catalyst-Driven Play in the TRD Market - AInvest
GH Research reports progress on FDA engagement for GH001 IND By Investing.com - Investing.com South Africa
GH Research Unveils Pivotal Program Plans Amidst Promising Trial Results - TipRanks
GH Research reports progress on FDA engagement for GH001 IND - Investing.com
GH Research Announces Global Pivotal Program Plans and Further Development Updates - The Manila Times
Breakthrough Depression Drug Shows 73% Remission Rate Over 6 Months in Phase 2b Study - Stock Titan
Best Dividend Growth Stocks AI Driven Stock ResearchExceptional portfolio growth - Autocar Professional
Is GH Research PLC a good long term investmentPhenomenal returns - jammulinksnews.com
Is GSAT a good long term investmentMassive portfolio appreciation - jammulinksnews.com
Best Stocks for Income Generation Strategic Wealth Building StocksPowerful profit generation - jammulinksnews.com
Cantor Fitzgerald Initiates Coverage of GH Research (GHRS) With Overweight Rating - MSN
What analysts say about WSO.B stockTremendous wealth creation - Autocar Professional
Best IPO Stocks in India Premium Stock Trading StrategiesLightning-fast capital gains - PrintWeekIndia
Punjab Communications Limited (500346)’s Trend in 2025Market-leading profit generation - Autocar Professional
Top Mining Stocks in India Professional Stock AnalysisGame-changing capital returns - PrintWeekIndia
Is LWLG a good long term investmentSuperior stock selection - jammulinksnews.com
Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade - MSN
Why GH Research PLC stock attracts strong analyst attentionProven Trading Plan - Newser
What drives ARGO.PRA stock priceRapid portfolio appreciation - jammulinksnews.com
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):